Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Korábbi kezelés

• Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators.
• Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria).
• Administration of a contraindicated drug is essential for medical purposes.
• Contraindications to the study drug (cerebrolysin).

Más betegség

• Patients with advanced liver, kidney, cardiac, or pulmonary disease.
• History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension.
• Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol.

Egyéb

• Patients with confirmed epileptiform discharges on EEG
• Patients with brain parenchymal defects
• Participation in another therapeutic study

• Patients with hemorrhagic stroke confirmed by CT or MRI
• Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke
• Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)
• Age: 19 to 80 years of age
• Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative.